manent disability compared with non-AF-associated cardioembolic strokes [5] . Therefore, stroke prevention in patients with AF is of paramount importance in everyday clinical practice. Several clinical studies and one meta-analysis reported on the of anticoagulation versus antithrombotic therapy alone [6] [7] [8] . For decades, oral anticoagulation treatment was performed nonselectively with vitamin K antagonists (VKA) like warfarin and phenprocoumon [9, 32] . Non-vitamin K oral anticoagulants (NOAC) are direct inhibitors either of thrombin (factor II; e.g., dabigatran-etexilate) or of factor Xa (apixaban, rivaroxaban, or edoxaban) and have revolutionized anticoagulation therapy [10] [11] [12] [13] . In this review we summarize the current scientific evidence and guideline recommendations for anticoagulation in AF.
NOAC phase III trials for stroke prevention in AF
Four large-scale randomized trials have compared NOAC therapy with OAC and warfarin (. Table 1 ; [10] [11] [12] [13] In the pivotal phase III trials, NOAC therapy was associated with similar or even lower bleeding risk than VKA therapy (. Fig. 1b ; [10] [11] [12] [13] ). On average, there was a 14% risk reduction in major bleeding events for NOAC therapy versus warfarin (HR = 0.86, 95% CI: 0.73-1.00, p = 0.06) [14] . Of note, however, there was a significant difference for heterogeneity, indicating that the effect on bleeding risk was different for the four NOACs. Specifically, there was a significant reduction in bleeding risk for apixaban and edoxaban in comparison with warfarin; for dabigatran and rivaroxaban, bleeding risk was similar to that of warfarin. [14] . Of particular note is the fact that the risk for the most feared complication of any type of OAC-risk of intracranial hemorrhage-was halved in those AF patients assigned to therapy with one of the NOACs (HR = 0.48, 95% CI: 0.39-0.59, p < 0.0001). Intracranial hemorrhage comprised both hemorrhagic stroke plus subdural hematoma. Gastrointestinal bleeds were more commonlyobserved withNOAC therapythan with VKA treatment (HR = 1.25, 95% CI: 1.01-1.55, p = 0.043; . Fig. 1c) , with the exception of apixaban.
In summary, the evidence stemming from four large-scale randomized trials demonstrates that NOAC therapy is at least as effective if not superior to OAC with VKA in patients with AF. Given their much simpler pharmacodynamic and pharmacokinetic properties, the clinical management of NOACs is much easier than that of VKA. Advantages include administration of fixed doses, lack of regular coagulation checks, rapid onset and effect of action, lack of significant interactions with food and drugs, just to name the most important ones.
Current guideline recommendations on the use of NOACs for stroke prevention in AF
The meticulous evaluation of the efficacy and safety of NOAC therapy in patients with AF has led to new recommendations for their use in most jurisdictions. The new2016 guideline recommendations for the management of AF of the European Society of Cardiology have clearly prioritized NOAC therapy over treatment with VAK for stroke prevention in patients with AF [9] . They state that: "When OAC is initiated in a patient with AF who is eligible for a NOAC (apixaban, dabigatran, edoxaban, rivaroxaban) an NOAC is recommended in preference to a VKA. " The only two exceptions to this rule are patients with moderate-to-severe mitral stenosis or with a mechanical heart valve; these patients cannot receive an NOAC and must be anticoagulated with a VKA Abstract Atrial fibrillation (AF) is the most frequently encountered sustained arrhythmia with a prevalence of 0.5-10%, depending predominantly on age. The arrhythmia is associated with significant morbidity and mortality, mainly due to thromboembolic events including stroke and systemic embolisms. These complications can be effectively prevented with anticoagulation therapy either with vitamin K antagonists (VKA) or with nonvitamin K antagonists (NOAC). VKA therapy is effective in preventing strokes but these medications are difficult to use, are associated with significant bleeding risk, and have pharmacokinetic/dynamic properties that make their use cumbersome. NOACs-either factor II or factor Xa inhibitors-have been developed over the past two decades and have been tested against VKA in large randomized controlled trials. This trial evidence was complemented more recently by increasing real-world data comprising several 100,000 patients. Finally, NOACs have been examined for their use in specific clinical situations, for example, in patients undergoing cardioversion, catheter ablation, or coronary interventions. In all of these clinical scenarios, NOACs have been similarly effective or-in many instances-even superior to treatment with VKA. Recent guidelines, therefore, recommend NOAC therapy for stroke prevention in AF as firstline therapy. 
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Vorhofflimmern · Antikoagulanzien · Vitamin-K-Antagonisten · Embolie · Blutung [9] . Similar recommendations have been released byothersocieties, e. g., the Canadian Cardiovascular Society [29] . In its recently published focused update for the management of AF, a flow chart to facilitate everyday decision-making on whether to initiate anticoagulation therapy or not is provided (. Fig. 2 ). The use of NOACs is preferred over warfarin in patients with risk factors for stroke corresponding to a CHA2DS2-VASc score of ≥2 [15] . 
Real-world data to support results of randomized controlled trials
In general, the efficacy and safety of a new therapy assessed in clinical trial settings may not necessarily be the same in routine practice because of differences in the patient populations (i. e., due to predefined specific inclusion and exclusion criteria of randomized trials), intensity of follow-up in experienced study centers, or the variations in care that patients receive [16] . Extrapolating findings from trials to general practice is especially challenging for anticoagulation therapies as they are long-term preventive medications that do not necessarily address ongoing symptoms. Medication adherence, for instance, is substantially lower in observational studies than in clinical trials [17] . Therefore, analysis of real-world data of NOAC use versus VKA use in terms of safety and efficacy might facilitate the interpretation of results obtained in randomized controlled trials [18] [19] [20] [21] .
Real-world data: safety of NOAC use
At present, a plethora of real-world studies are complementing the results of the randomized trials. In one of the largest of these studies, Yao and colleagues analyzed U.S. insurance data using warfarin, apixaban, rivaroxaban, or dabigatran for stroke prevention in non-valvular AF between 2010 and 2015 [18] . The authors created three patient cohorts using 1:1 propensity score matching: apixaban versus warfarin (n = 15,390), dabigatran versus warfarin (n = 28,614), and rivaroxaban versus warfarin (n = 32,350). For major bleeding (including intracranial hemorrhage, gastrointestinal bleeding, or bleeding from other sites), apixaban and dabigatran were associated with a lower risk (HR = 0.45, 95% CI: 0.34-0.59, p < 0.001; HR = 0.79, 95% CI: 0.67-0.94, p < 0.01), and rivaroxaban was associated with a similar risk, compared with warfarin (HR = 1.04, 95% CI: 0.90-1.20, p = 0.60). Most importantly, all three NOACs were associated with a lower risk of intracranial bleeding [18] .
Another example of real-world data is the report by Lip and colleagues analyzing insurance data of 45,361 AF patients newly on anticoagulation treatment (≥1 year) with either warfarin (34.1%), apixaban (16.4%), rivaroxaban (39.2%), or dabigatran (10.3%) [19] . Compared with propensity-score-matched warfarin initiators, apixaban and dabigatran initiators had a significantly lower risk of major bleeding (HR = 0.53, 95% CI: 0.39-0.71; HR = 0.69, 95% CI: 0.50-0.96, respectively). Patients on rivaroxaban had a nonsignificant difference in major bleeding risk compared with matched warfarin patients (HR = 0.98, 95% CI: 0.83-1.17). The authors went on to compare bleeding outcomes between NOACs, revealing a significantly higher risk of major bleeding in rivaroxaban patients (HR: 1.82, 95% CI: 1.36-2.43) compared with apixaban patients. The differences for apixaban-dabigatran and dabigatran-rivaroxaban matched cohorts were not statistically significant [19] . [21] These findings have been recently confirmed by Deitelzweig and colleagues, who analyzed real-world data of almost 500,000 AF patients on anticoagulant treatment with NOACs or VKA in a meta-analysis comprising 26 studies [20] . Ten of these studies were industrysponsored and 13 were investigator-initiated. Apixaban showed a significantly lower risk of major bleeding versus warfarin. Major bleeding risk was either significantly lower (n = 9 of 16 studies) or not significantly different (n = 7 of 16 studies) between dabigatran and warfarin. Bleeding risks were similar for rivaroxaban and warfarin. Of note, there were no differences in results (i. e., bleeding events with NOAC vs. VKA therapy) between industry-and nonindustry-sponsored studies [20] .
In Germany, phenprocoumon is the most commonly used VKA. This VKA differs significantly in terms of pharmacokinetic and pharmacodynamic properties from warfarin (most importantly, a much longer half-life and an even slower onset and offset of anticoagulation activity). Phenprocoumon has recently been compared with NOACs in a study performed on German insurance claims [21] 
Real-world data: efficacy of NOAC use
There is also real-world evidence concerning the efficacy of NOACs in prevention of stroke and systemic embolism. For instance, Yao and colleagues using Cox proportional hazards regression found a lower stroke risk for patients on apixaban compared with patients on warfarin (HR = 0.67, 95% CI: 0.46-0.98, p = 0.04) The reduction was driven mainly by the lower risk of hemorrhagic stroke (HR 0.35, 95% CI: 0.14-0.88, p = 0.03) [18] . Although dabigatran and rivaroxaban use were associated with a similar risk for stroke and systemic [23, [27] [28] [29] . pts Patients, RCT randomized controlled trial, TEE transesophageal echocardiography p = 0.56). Nonetheless, the risk of hemorrhagic stroke was numerically lower in patients on dabigatran (HR = 0.56, 95% CI: 0.30-1.04, p = 0.07) as well as those on rivaroxaban (HR = 0.61, 95% CI: 0.35-1.07, p = 0.08) when compared with patients on warfarin [18] .
In summary, a plethora of real-world data complement observations made in the pivotal randomized NOAC anticoagulation trials. All of these studies yield remarkably similar and constant results. There is no doubt that NOAC therapy is associated with similar (rivaroxaban) or even significantly lower bleeding risk (apixaban, dabigatran) compared with VKA treatment. Similarly, realworld data concerning stroke prevention demonstrate superiority of NOACs over VKA.
NOAC therapy in specific clinical situations
NOAC therapy in the setting of cardioversion
Restoration of sinus rhythm by means of cardioversion is often mandatory in highly symptomatic AF patients [9] . The periprocedural risk of thromboembolic events associated with cardioversion is well recognized, with stroke rates between 0.4 and 2.3% in non-anticoagulated patients [22] . Current guidelines recommend anticoagulation for ≥3 weeks before elective cardioversion and at least 4 weeks thereafter in patients with AF episodes lasting ≥48 h or with AF of unknown duration, regardless of their stroke risk profile and type of cardioversion procedure (electrical or pharmacologic) [9] . Post hoc analyses of all randomized NOAC trials concerning anticoagulation in patients undergoing cardioversion have demonstrated a similar or lower risk of stroke/systemic embolism and similar bleeding complications compared with VKA [23] [24] [25] [26] .
More recently, dedicated prospective trials have been conducted with patients undergoing cardioversion comparing VKA versus rivaroxaban [27] , edoxaban [28] , or apixaban [29] . These studies have enrolled between 1270 and 2199 patients scheduled for rapid or delayed cardioversion (. Fig. 4) . None of these trials was statistically powered to formally test superiority or noninferiority of NOAC versus VKA therapy. All studies showed relatively low event rates both for thromboembolic and bleeding outcomes, without significant differences between the treatment arms [27] [28] [29] . . Fig. 4 summarizes the anticoagulation strategies and durations before and after cardioversion applied in the recent randomized controlled trials [23, [27] [28] [29] .
NOAC therapy in the setting of catheter ablation
Catheter ablation is a well-established treatment for symptomatic AF endorsed by recent guidelines [9, 30] . Among the most important complications of AF ablation are periprocedural stroke or transient ischemic attack (TIA) as well as bleeding events, particularly cardiac tamponade [30] . Hence, anticoagulation therapy around the ablation procedure is of particular importance. For many years, periprocedural anticoagulation therapy was halted and bridging with heparin was instituted. A randomized controlled trial comparing uninterrupted versus interrupted VKA therapy demonstrated superiority of the uninterrupted therapy [31] . In the COMPARE trial, patients with a CHA2DS2 score ≥1 were included. Patients were randomly assigned in a 1:1 ratio to the off-warfarin or on-warfarin arm. The incidence of thromboembolic events in the 48 h after ablation was the primary endpoint of the study. The study enrolled 1584 patients: 790 assigned to discontinue warfarin and 794 assigned to continuous warfarin. Warfarin discontinuation emerged as a strong predictor of periprocedural thromboembolism (OR = 1.30, 95% CI: 3.1-55.6, p < 0.001) [31] . A number of uncontrolled observational studies have then tested various NOAC strategies and found comparable bleeding and thromboembolic complications versus VKA treatment [32] .
In the VENTURE-AF trial, 248 patients with non-valvular AF were randomly assigned to either uninterrupted rivaroxaban (20 mg once daily) or to an uninterrupted VKA prior to catheter ablation and for 4 weeks afterwards. The primary endpoint was major bleeding; secondary endpoints were thromboembolic events. During follow-up, one major bleeding occurred as well as one stroke and one vascular death (all events in the VKA group), proving the feasibility of uninterrupted rivaroxaban use in patients undergoing catheter ablation [33] .
The second dedicated randomized trial (RE-CIRCUIT study) compared uninterrupted dabigatran therapy (150 mg BID) and uninterrupted warfarin therapy [34] . In the RE-CIRCUIT trial, 635 patients received VKA or dabigatran 4-8 weeks prior to ablation and at least 4 weeks after ablation. Patients randomized to dabigatran took their morning dose on the day of ablation and their evening dose with a delay of at least 3 h after sheath removal; patients on VKA were monitored to achieve an international normalized ratio (INR) of 2-3. The incidence of major bleeding events during and up to 8 weeks after ablation was lower with dabigatran than with warfarin (5 patients [34] .
A recently published meta-analysis comprising 12 studies and 4962 patients analyzing uninterrupted NOAC versus VKA use in patients with AF undergoing catheter ablation showed comparable stroke/TIA rates (NOAC, 0.08%; VKA, 0.16%; OR =0.66, 95% CI: 0.19-2.30). Furthermore, major bleeding was significantly reduced in the NOAC group (0.9%) compared with VKA-treated patients (2.0%) (OR =0.50, 95% CI: 0.30-0.84, p < 0.01) [35] , proving that uninterrupted anticoagulation in patients undergoing ablation is a feasible treatment.
Coronary interventions/PCI
Approximately 5-15% of patients with AF will require coronary stenting either due to progressive coronary artery disease or in the setting of an acute coronary syndrome [36] . For further prevention of cardiovascular events including stent thrombosis, dual antiplatelet therapy (DAPT) with aspirin plus a P2Y12 inhibitor is indicated. Therefore, guidelines recommend both anticoagulation and DAPT (triple therapy) in AF for various treatment durations [9, 36] . However, triple therapy is associated with high rates of major bleeding [37] , especially when newer more potent P2Y12 inhibitors are used [38] .
In the PIONEER-AF study, 2124 patients with nonvalvular AF who had undergone percutaneous coronary intervention (PCI) with stenting were randomized to receive either low-dose rivaroxaban (15 mg once daily) plus a P2Y12 inhibitor for 12 months (group 1), very-low-dose rivaroxaban (2.5 mg twice daily) plus DAPT for 1, 6, or 12 months (group 2), or standard therapy with a dose-adjusted VKA (once daily) plus DAPT for 1, 6, or 12 months (group 3). The primary safety outcome was clinically significant bleeding. The rates of clinically significant bleeding were lower in the two groups receiving rivaroxaban than in the group receiving standard therapy (16.8% in group 1, 18.0% in group 2, and 26.7% in group 3; group 1 vs. group 3 HR = 0.59, 95% CI: 0.47-0.76, p < 0.001; group 2 vs. group 3 HR = 0.63, 95% CI: 0.50-0.80, p < 0.001) [39] .
The second randomized trial to compare dual versus triple anticoagulation strategy was the RE-DUAL trial [40] . In this multicenter trial, 2725 AF patients who had undergone PCI were randomly assigned to triple therapy (warfarin plus a P2Y12 inhibitor [clopidogrel or ticagrelor], and aspirin for 1-3 months; triple-therapy group) or dual therapy with dabigatran (110 or 150 mg twice daily) plus a P2Y12 inhibitor (clopidogrel or ticagrelor) without aspirin (110 mg and 150 mg dual-therapy groups). The primary endpoint was a major or clinically relevant nonmajor bleeding event during a mean follow-up of 14 months. The incidence of the primary endpoint was 15.4% in the 110-mg dual-therapy group compared with 26.9% in the triple-therapy group (HR = 0.52, 95% CI: 0.42-0.63, p < 0.001 for noninferiority; p < 0.001 for superiority) and 20.2% in the 150-mg dual-therapy group compared with 25.7% in the corresponding triple-therapy group (HR = 0.72, 95% CI: 0.58-0.88, p < 0.001 for noninferiority). The absolute reduction in the primary endpoint was 11.8% for the dabigatran 110-mg strategy and 5.2% for the dabigatran 150-mg strategy. The composite efficacy endpoint (death, thromboembolic events, unplanned revascularization) met noninferiority criteria for the dual strategy (13.7%) versus triple therapy (13.4%) (HR = 1.04, 95% CI: 0.84-1.29, p = 0.005 for noninferiority) [40] .
In summary, the PIONEER-AF and RE-DUAL trials demonstrate that a dual strategy of an NOAC plus a P2Y12 inhibitor results in significantly fewer bleeding complications after coronary stenting than triple therapy with VKA, aspirin, and a P2Y12 inhibitor. There are two more randomized studies underway testing apixaban and edoxaban for dual strategy after coronary stenting.
Conclusion and clinical implications
NOAC therapy represents the first-line therapy for stroke prevention in patients with AF because it is more efficacious and safer than VKA. For that reason, current AF management guidelines prioritize NOACs over warfarin. After more than 50 years of VKA use, there is still no specific reversal agent for warfarin/phenprocoumon. By contrast, dabigatran is the first of the NOACs that has a specific reversal agent available, idarucizumab, a humanized antibody fragment that binds dabigatran and rapidly and dose-dependently reverses its effects within less than 2 min. Soon, there will also be a reversal agent for factor Xa inhibitors. This will help to make NOAC treatment even safer than it is presently.
